IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12194051 B1

PDFFull Text
Date of Patent:
Jan. 14, 2025

Filed:

Oct. 22, 2019

5-azaindazole derivatives as adenosine receptor antagonists

Applicant:

Merck Patent Gmbh, Darmstadt, DE;

Inventors:

Anne-Laure Blayo, Credin, FR;

Baptiste Manteau, Ways, BE;

Camille Amalric, Strassbourg, FR;

Stanislas Mayer, Eschau, FR;

Stephan Schann, Illkirch, FR;

Mickaël Fer, Ostwald, FR;

Assignee:

MERCK PATENT GMBH, Darmstadt, DE;

Attorneys:

Millen White Zelano & Branigan

Csaba Henter

Primary Examiner:

Bruck Kifle

Assistant Examiner:

Kevin S Martin

Int. Cl.
CPC ...
A61K 31/553 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/5386 (2006.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61P 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/553 (2013.01); A61K 31/4545 (2013.01); A61K 31/46 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5386 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01);
Abstract

The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A/Aadenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

Find Patent Forward Citations

Loading…